Wentz Melissa J, Jamaluddin Mohammad, Garfield Robert E, Al-Hendy Ayman
Department of Obstetrics & Gynecology, University of Texas Medical Branch, Galveston, Texas 77555, USA.
Obstet Gynecol. 2006 Dec;108(6):1439-47. doi: 10.1097/01.AOG.0000243775.73788.11.
The catechol-O-methyltransferase enzyme catalyzes the methylation of the catechol estrogens, 2- or 4-hydroxyestrogen, to 2- or 4-methoxyestrogen. Both the hydroxy estrogens and methoxy estrogens were shown to modulate the effects of estrogen. Because catechol-O-methyltransferase activity controls levels of these metabolites, it may help regulate the cellular estrogenic milieu. In this study, we examined the regulation of catechol-O-methyltransferase expression in human myometrial cells.
Catechol-O-methyltransferase expression was assessed by reverse transcription-polymerase chain reaction, Western blot, and luciferase assays in human myometrial cells after treatment with estrogen or progesterone. Catechol-O-methyltransferase expression was measured in cells after treatment with tumor necrosis factor alpha (TNFalpha) alone or with lactacystin, a proteasome inhibitor. Luciferase assays were also conducted using human myometrial cells containing an estrogen response element-luciferase reporter gene to measure levels of estrogen-mediated transactivation after treatment with estrogen and increasing concentrations of 2-hydroxestrogen.
Catechol-O-methyltransferase expression was down-regulated by progesterone or estrogen. Tumor necrosis factor alpha upregulated catechol-O-methyltransferase expression, whereas cotreatment with lactacystin attenuated this response, suggesting that TNFalpha activated nuclear factor kappa B to induce catechol-O-methyltransferase expression. Increased concentrations of 2-hydroxyestrogen attenuated estrogen-mediated transcription in the myometrial cells.
Catechol-O-methyltransferase expression may be regulated in the myometrium to control the local action of estrogen. Low levels of catechol-O-methyltransferase in the myometrium would result in an accumulation of 2-hydroxyestrogen and may antagonize the local effect of estrogen. High levels of catechol-O-methyltransferase in the myometrium would result in lower levels of 2-hydroxyestrogen and may increase sensitivity to estrogen.
儿茶酚-O-甲基转移酶催化儿茶酚雌激素(2-或4-羟基雌激素)甲基化生成2-或4-甲氧基雌激素。已证实羟基雌激素和甲氧基雌激素均可调节雌激素的作用。由于儿茶酚-O-甲基转移酶活性控制这些代谢产物的水平,其可能有助于调节细胞内雌激素环境。在本研究中,我们检测了人子宫肌层细胞中儿茶酚-O-甲基转移酶表达的调控情况。
在用雌激素或孕激素处理后人子宫肌层细胞中,通过逆转录-聚合酶链反应、蛋白质印迹法和荧光素酶测定评估儿茶酚-O-甲基转移酶的表达。在用肿瘤坏死因子α(TNFα)单独处理或与蛋白酶体抑制剂乳胞素共同处理后的细胞中测量儿茶酚-O-甲基转移酶的表达。还使用含有雌激素反应元件-荧光素酶报告基因的人子宫肌层细胞进行荧光素酶测定,以测量在用雌激素和增加浓度的2-羟基雌激素处理后雌激素介导的转录激活水平。
孕激素或雌激素可下调儿茶酚-O-甲基转移酶的表达。肿瘤坏死因子α上调儿茶酚-O-甲基转移酶的表达,而与乳胞素共同处理可减弱此反应,提示TNFα激活核因子κB以诱导儿茶酚-O-甲基转移酶的表达。2-羟基雌激素浓度增加可减弱子宫肌层细胞中雌激素介导的转录。
子宫肌层中儿茶酚-O-甲基转移酶的表达可能受到调控以控制雌激素的局部作用。子宫肌层中儿茶酚-O-甲基转移酶水平低会导致2-羟基雌激素蓄积,并可能拮抗雌激素的局部作用。子宫肌层中儿茶酚-O-甲基转移酶水平高会导致2-羟基雌激素水平降低,并可能增加对雌激素的敏感性。